Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure.

NCT00461058 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00461058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00461058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
December 31, 2007
Enrollment
14 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2